nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Methotrexate—lymphatic system cancer	0.595	1	CbGbCtD
Brimonidine—Pain of skin—Bleomycin—lymphatic system cancer	0.0162	0.04	CcSEcCtD
Brimonidine—Conjunctival oedema—Carmustine—lymphatic system cancer	0.012	0.0297	CcSEcCtD
Brimonidine—Hyperaemia—Carmustine—lymphatic system cancer	0.0111	0.0273	CcSEcCtD
Brimonidine—Blindness—Fludarabine—lymphatic system cancer	0.00942	0.0232	CcSEcCtD
Brimonidine—Osteoporosis—Fludarabine—lymphatic system cancer	0.0093	0.0229	CcSEcCtD
Brimonidine—Cyanosis—Teniposide—lymphatic system cancer	0.00838	0.0207	CcSEcCtD
Brimonidine—Hypoxia—Fludarabine—lymphatic system cancer	0.00821	0.0203	CcSEcCtD
Brimonidine—Pallor—Teniposide—lymphatic system cancer	0.00716	0.0177	CcSEcCtD
Brimonidine—Blindness—Vincristine—lymphatic system cancer	0.00575	0.0142	CcSEcCtD
Brimonidine—Respiratory failure—Fludarabine—lymphatic system cancer	0.00531	0.0131	CcSEcCtD
Brimonidine—Burning sensation—Carmustine—lymphatic system cancer	0.0048	0.0119	CcSEcCtD
Brimonidine—Coma—Fludarabine—lymphatic system cancer	0.00476	0.0118	CcSEcCtD
Brimonidine—Depression—Mechlorethamine—lymphatic system cancer	0.00449	0.0111	CcSEcCtD
Brimonidine—Scotoma—Carmustine—lymphatic system cancer	0.00439	0.0108	CcSEcCtD
Brimonidine—Visual disturbance—Fludarabine—lymphatic system cancer	0.00399	0.00985	CcSEcCtD
Brimonidine—Respiratory failure—Vincristine—lymphatic system cancer	0.00324	0.008	CcSEcCtD
Brimonidine—Bronchitis—Fludarabine—lymphatic system cancer	0.00315	0.00776	CcSEcCtD
Brimonidine—Coma—Carmustine—lymphatic system cancer	0.00305	0.00752	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00297	0.00734	CcSEcCtD
Brimonidine—Coma—Vincristine—lymphatic system cancer	0.00291	0.00718	CcSEcCtD
Brimonidine—Abnormal vision—Carmustine—lymphatic system cancer	0.00291	0.00718	CcSEcCtD
Brimonidine—Arthritis—Bleomycin—lymphatic system cancer	0.00286	0.00704	CcSEcCtD
Brimonidine—Infection—Mechlorethamine—lymphatic system cancer	0.00285	0.00704	CcSEcCtD
Brimonidine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00279	0.00688	CcSEcCtD
Brimonidine—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00279	0.00687	CcSEcCtD
Brimonidine—Flushing—Teniposide—lymphatic system cancer	0.00277	0.00682	CcSEcCtD
Brimonidine—Osteoporosis—Methotrexate—lymphatic system cancer	0.00276	0.0068	CcSEcCtD
Brimonidine—Swelling—Carmustine—lymphatic system cancer	0.00275	0.00677	CcSEcCtD
Brimonidine—Sinusitis—Fludarabine—lymphatic system cancer	0.00274	0.00675	CcSEcCtD
Brimonidine—Eye pain—Carmustine—lymphatic system cancer	0.00268	0.00662	CcSEcCtD
Brimonidine—Arrhythmia—Teniposide—lymphatic system cancer	0.00266	0.00657	CcSEcCtD
Brimonidine—Pharyngitis—Fludarabine—lymphatic system cancer	0.0026	0.00641	CcSEcCtD
Brimonidine—Swelling—Mitoxantrone—lymphatic system cancer	0.00255	0.0063	CcSEcCtD
Brimonidine—Visual impairment—Fludarabine—lymphatic system cancer	0.00252	0.00623	CcSEcCtD
Brimonidine—Hypoxia—Methotrexate—lymphatic system cancer	0.00243	0.006	CcSEcCtD
Brimonidine—Arrhythmia—Fludarabine—lymphatic system cancer	0.00234	0.00577	CcSEcCtD
Brimonidine—Face oedema—Carmustine—lymphatic system cancer	0.00234	0.00577	CcSEcCtD
Brimonidine—Hypertension—Teniposide—lymphatic system cancer	0.00224	0.00552	CcSEcCtD
Brimonidine—Burning sensation—Methotrexate—lymphatic system cancer	0.00222	0.00549	CcSEcCtD
Brimonidine—Chest pain—Teniposide—lymphatic system cancer	0.00221	0.00545	CcSEcCtD
Brimonidine—Cyanosis—Methotrexate—lymphatic system cancer	0.00218	0.00539	CcSEcCtD
Brimonidine—Oedema—Teniposide—lymphatic system cancer	0.00212	0.00522	CcSEcCtD
Brimonidine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00212	0.00522	CcSEcCtD
Brimonidine—Infection—Teniposide—lymphatic system cancer	0.0021	0.00519	CcSEcCtD
Brimonidine—Tachycardia—Teniposide—lymphatic system cancer	0.00207	0.0051	CcSEcCtD
Brimonidine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00203	0.00501	CcSEcCtD
Brimonidine—Cough—Fludarabine—lymphatic system cancer	0.00199	0.00491	CcSEcCtD
Brimonidine—Hypotension—Teniposide—lymphatic system cancer	0.00198	0.00488	CcSEcCtD
Brimonidine—Arthralgia—Fludarabine—lymphatic system cancer	0.00194	0.00479	CcSEcCtD
Brimonidine—Myalgia—Fludarabine—lymphatic system cancer	0.00194	0.00479	CcSEcCtD
Brimonidine—Discomfort—Fludarabine—lymphatic system cancer	0.00192	0.00473	CcSEcCtD
Brimonidine—Dyspnoea—Teniposide—lymphatic system cancer	0.00189	0.00466	CcSEcCtD
Brimonidine—Depression—Carmustine—lymphatic system cancer	0.00186	0.00459	CcSEcCtD
Brimonidine—Oedema—Fludarabine—lymphatic system cancer	0.00186	0.00459	CcSEcCtD
Brimonidine—Infection—Fludarabine—lymphatic system cancer	0.00185	0.00456	CcSEcCtD
Brimonidine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00182	0.0045	CcSEcCtD
Brimonidine—Apnoea—Methotrexate—lymphatic system cancer	0.00182	0.0045	CcSEcCtD
Brimonidine—Rash—Mechlorethamine—lymphatic system cancer	0.00181	0.00447	CcSEcCtD
Brimonidine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00181	0.00446	CcSEcCtD
Brimonidine—Flushing—Bleomycin—lymphatic system cancer	0.00178	0.0044	CcSEcCtD
Brimonidine—Depression—Vincristine—lymphatic system cancer	0.00178	0.00438	CcSEcCtD
Brimonidine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00174	0.00428	CcSEcCtD
Brimonidine—Nausea—Mechlorethamine—lymphatic system cancer	0.00171	0.00421	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00169	0.00418	CcSEcCtD
Brimonidine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00169	0.00416	CcSEcCtD
Brimonidine—Erythema—Bleomycin—lymphatic system cancer	0.00167	0.00412	CcSEcCtD
Brimonidine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00167	0.00412	CcSEcCtD
Brimonidine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00166	0.00409	CcSEcCtD
Brimonidine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00164	0.00404	CcSEcCtD
Brimonidine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00163	0.00402	CcSEcCtD
Brimonidine—Visual impairment—Carmustine—lymphatic system cancer	0.00162	0.00398	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00161	0.00396	CcSEcCtD
Brimonidine—Fatigue—Fludarabine—lymphatic system cancer	0.0016	0.00396	CcSEcCtD
Brimonidine—Pain—Fludarabine—lymphatic system cancer	0.00159	0.00392	CcSEcCtD
Brimonidine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00159	0.00391	CcSEcCtD
Brimonidine—Respiratory failure—Methotrexate—lymphatic system cancer	0.00157	0.00388	CcSEcCtD
Brimonidine—Eye disorder—Carmustine—lymphatic system cancer	0.00157	0.00386	CcSEcCtD
Brimonidine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00156	0.00385	CcSEcCtD
Brimonidine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00156	0.00385	CcSEcCtD
Brimonidine—Flushing—Carmustine—lymphatic system cancer	0.00156	0.00384	CcSEcCtD
Brimonidine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00155	0.00381	CcSEcCtD
Brimonidine—Asthenia—Teniposide—lymphatic system cancer	0.00152	0.00375	CcSEcCtD
Brimonidine—Pruritus—Teniposide—lymphatic system cancer	0.0015	0.00369	CcSEcCtD
Brimonidine—Arrhythmia—Carmustine—lymphatic system cancer	0.0015	0.00369	CcSEcCtD
Brimonidine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00148	0.00366	CcSEcCtD
Brimonidine—Mental disorder—Carmustine—lymphatic system cancer	0.00147	0.00362	CcSEcCtD
Brimonidine—Erythema—Carmustine—lymphatic system cancer	0.00146	0.0036	CcSEcCtD
Brimonidine—Cough—Bleomycin—lymphatic system cancer	0.00146	0.0036	CcSEcCtD
Brimonidine—Angiopathy—Vincristine—lymphatic system cancer	0.00145	0.00358	CcSEcCtD
Brimonidine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00144	0.00356	CcSEcCtD
Brimonidine—Chest pain—Bleomycin—lymphatic system cancer	0.00142	0.00351	CcSEcCtD
Brimonidine—Myalgia—Bleomycin—lymphatic system cancer	0.00142	0.00351	CcSEcCtD
Brimonidine—Coma—Methotrexate—lymphatic system cancer	0.00141	0.00348	CcSEcCtD
Brimonidine—Discomfort—Bleomycin—lymphatic system cancer	0.00141	0.00347	CcSEcCtD
Brimonidine—Mental disorder—Vincristine—lymphatic system cancer	0.0014	0.00346	CcSEcCtD
Brimonidine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00139	0.00343	CcSEcCtD
Brimonidine—Vision blurred—Carmustine—lymphatic system cancer	0.00137	0.00339	CcSEcCtD
Brimonidine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00137	0.00338	CcSEcCtD
Brimonidine—Oedema—Bleomycin—lymphatic system cancer	0.00136	0.00337	CcSEcCtD
Brimonidine—Erythema—Mitoxantrone—lymphatic system cancer	0.00136	0.00335	CcSEcCtD
Brimonidine—Infection—Bleomycin—lymphatic system cancer	0.00136	0.00334	CcSEcCtD
Brimonidine—Asthenia—Fludarabine—lymphatic system cancer	0.00133	0.00329	CcSEcCtD
Brimonidine—Rash—Teniposide—lymphatic system cancer	0.00133	0.00329	CcSEcCtD
Brimonidine—Dermatitis—Teniposide—lymphatic system cancer	0.00133	0.00329	CcSEcCtD
Brimonidine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00133	0.00328	CcSEcCtD
Brimonidine—Headache—Teniposide—lymphatic system cancer	0.00133	0.00327	CcSEcCtD
Brimonidine—Pruritus—Fludarabine—lymphatic system cancer	0.00132	0.00325	CcSEcCtD
Brimonidine—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00129	0.00318	CcSEcCtD
Brimonidine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00128	0.00315	CcSEcCtD
Brimonidine—Hypotension—Bleomycin—lymphatic system cancer	0.00127	0.00314	CcSEcCtD
Brimonidine—Hypertension—Carmustine—lymphatic system cancer	0.00126	0.00311	CcSEcCtD
Brimonidine—Nausea—Teniposide—lymphatic system cancer	0.00126	0.0031	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00124	0.00307	CcSEcCtD
Brimonidine—Myalgia—Carmustine—lymphatic system cancer	0.00124	0.00306	CcSEcCtD
Brimonidine—Chest pain—Carmustine—lymphatic system cancer	0.00124	0.00306	CcSEcCtD
Brimonidine—Anxiety—Carmustine—lymphatic system cancer	0.00124	0.00305	CcSEcCtD
Brimonidine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00122	0.00302	CcSEcCtD
Brimonidine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00122	0.003	CcSEcCtD
Brimonidine—Hypertension—Vincristine—lymphatic system cancer	0.0012	0.00297	CcSEcCtD
Brimonidine—Oedema—Carmustine—lymphatic system cancer	0.00119	0.00294	CcSEcCtD
Brimonidine—Myalgia—Vincristine—lymphatic system cancer	0.00119	0.00293	CcSEcCtD
Brimonidine—Visual disturbance—Methotrexate—lymphatic system cancer	0.00118	0.00292	CcSEcCtD
Brimonidine—Cough—Mitoxantrone—lymphatic system cancer	0.00118	0.00292	CcSEcCtD
Brimonidine—Infection—Carmustine—lymphatic system cancer	0.00118	0.00292	CcSEcCtD
Brimonidine—Rash—Fludarabine—lymphatic system cancer	0.00117	0.00289	CcSEcCtD
Brimonidine—Dermatitis—Fludarabine—lymphatic system cancer	0.00117	0.00289	CcSEcCtD
Brimonidine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00117	0.00289	CcSEcCtD
Brimonidine—Pain—Bleomycin—lymphatic system cancer	0.00117	0.00288	CcSEcCtD
Brimonidine—Headache—Fludarabine—lymphatic system cancer	0.00117	0.00288	CcSEcCtD
Brimonidine—Tachycardia—Carmustine—lymphatic system cancer	0.00116	0.00287	CcSEcCtD
Brimonidine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00115	0.00285	CcSEcCtD
Brimonidine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00115	0.00285	CcSEcCtD
Brimonidine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00115	0.00285	CcSEcCtD
Brimonidine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00115	0.00284	CcSEcCtD
Brimonidine—Lethargy—Methotrexate—lymphatic system cancer	0.00115	0.00282	CcSEcCtD
Brimonidine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00114	0.00281	CcSEcCtD
Brimonidine—Oedema—Vincristine—lymphatic system cancer	0.00114	0.0028	CcSEcCtD
Brimonidine—Infection—Vincristine—lymphatic system cancer	0.00113	0.00279	CcSEcCtD
Brimonidine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00112	0.00277	CcSEcCtD
Brimonidine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00111	0.00275	CcSEcCtD
Brimonidine—Hypotension—Carmustine—lymphatic system cancer	0.00111	0.00274	CcSEcCtD
Brimonidine—Oedema—Mitoxantrone—lymphatic system cancer	0.00111	0.00273	CcSEcCtD
Brimonidine—Nausea—Fludarabine—lymphatic system cancer	0.00111	0.00273	CcSEcCtD
Brimonidine—Infection—Mitoxantrone—lymphatic system cancer	0.0011	0.00271	CcSEcCtD
Brimonidine—Shock—Mitoxantrone—lymphatic system cancer	0.00109	0.00269	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00108	0.00268	CcSEcCtD
Brimonidine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00108	0.00267	CcSEcCtD
Brimonidine—Insomnia—Carmustine—lymphatic system cancer	0.00108	0.00266	CcSEcCtD
Brimonidine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00108	0.00265	CcSEcCtD
Brimonidine—Paraesthesia—Carmustine—lymphatic system cancer	0.00107	0.00264	CcSEcCtD
Brimonidine—Hypotension—Vincristine—lymphatic system cancer	0.00106	0.00262	CcSEcCtD
Brimonidine—Dyspnoea—Carmustine—lymphatic system cancer	0.00106	0.00262	CcSEcCtD
Brimonidine—Somnolence—Carmustine—lymphatic system cancer	0.00106	0.00261	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00104	0.00255	CcSEcCtD
Brimonidine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00103	0.00255	CcSEcCtD
Brimonidine—Insomnia—Vincristine—lymphatic system cancer	0.00103	0.00254	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00103	0.00254	CcSEcCtD
Brimonidine—Paraesthesia—Vincristine—lymphatic system cancer	0.00102	0.00252	CcSEcCtD
Brimonidine—Pain—Carmustine—lymphatic system cancer	0.00102	0.00251	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00101	0.00249	CcSEcCtD
Brimonidine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.001	0.00248	CcSEcCtD
Brimonidine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000994	0.00245	CcSEcCtD
Brimonidine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000987	0.00243	CcSEcCtD
Brimonidine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000984	0.00243	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000981	0.00242	CcSEcCtD
Brimonidine—Fatigue—Vincristine—lymphatic system cancer	0.00098	0.00242	CcSEcCtD
Brimonidine—Asthenia—Bleomycin—lymphatic system cancer	0.000979	0.00241	CcSEcCtD
Brimonidine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000974	0.0024	CcSEcCtD
Brimonidine—Pain—Vincristine—lymphatic system cancer	0.000972	0.0024	CcSEcCtD
Brimonidine—Pruritus—Bleomycin—lymphatic system cancer	0.000965	0.00238	CcSEcCtD
Brimonidine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000954	0.00235	CcSEcCtD
Brimonidine—Pain—Mitoxantrone—lymphatic system cancer	0.000947	0.00234	CcSEcCtD
Brimonidine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000877	0.00216	CcSEcCtD
Brimonidine—Drowsiness—Methotrexate—lymphatic system cancer	0.000865	0.00213	CcSEcCtD
Brimonidine—Depression—Methotrexate—lymphatic system cancer	0.000862	0.00213	CcSEcCtD
Brimonidine—Rash—Bleomycin—lymphatic system cancer	0.00086	0.00212	CcSEcCtD
Brimonidine—Dermatitis—Bleomycin—lymphatic system cancer	0.000859	0.00212	CcSEcCtD
Brimonidine—Asthenia—Carmustine—lymphatic system cancer	0.000854	0.00211	CcSEcCtD
Brimonidine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000841	0.00207	CcSEcCtD
Brimonidine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000837	0.00207	CcSEcCtD
Brimonidine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000816	0.00201	CcSEcCtD
Brimonidine—Asthenia—Vincristine—lymphatic system cancer	0.000815	0.00201	CcSEcCtD
Brimonidine—Nausea—Bleomycin—lymphatic system cancer	0.00081	0.002	CcSEcCtD
Brimonidine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000794	0.00196	CcSEcCtD
Brimonidine—Dizziness—Carmustine—lymphatic system cancer	0.000787	0.00194	CcSEcCtD
Brimonidine—Pharyngitis—Methotrexate—lymphatic system cancer	0.00077	0.0019	CcSEcCtD
Brimonidine—Dizziness—Vincristine—lymphatic system cancer	0.000752	0.00185	CcSEcCtD
Brimonidine—Rash—Carmustine—lymphatic system cancer	0.000751	0.00185	CcSEcCtD
Brimonidine—Dermatitis—Carmustine—lymphatic system cancer	0.00075	0.00185	CcSEcCtD
Brimonidine—Visual impairment—Methotrexate—lymphatic system cancer	0.000748	0.00185	CcSEcCtD
Brimonidine—Headache—Carmustine—lymphatic system cancer	0.000746	0.00184	CcSEcCtD
Brimonidine—Eye disorder—Methotrexate—lymphatic system cancer	0.000725	0.00179	CcSEcCtD
Brimonidine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00072	0.00178	CcSEcCtD
Brimonidine—Rash—Vincristine—lymphatic system cancer	0.000717	0.00177	CcSEcCtD
Brimonidine—Dermatitis—Vincristine—lymphatic system cancer	0.000716	0.00177	CcSEcCtD
Brimonidine—Headache—Vincristine—lymphatic system cancer	0.000712	0.00176	CcSEcCtD
Brimonidine—Nausea—Carmustine—lymphatic system cancer	0.000707	0.00174	CcSEcCtD
Brimonidine—Angiopathy—Methotrexate—lymphatic system cancer	0.000704	0.00174	CcSEcCtD
Brimonidine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000701	0.00173	CcSEcCtD
Brimonidine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.0007	0.00173	CcSEcCtD
Brimonidine—Rash—Mitoxantrone—lymphatic system cancer	0.000698	0.00172	CcSEcCtD
Brimonidine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000697	0.00172	CcSEcCtD
Brimonidine—Headache—Mitoxantrone—lymphatic system cancer	0.000693	0.00171	CcSEcCtD
Brimonidine—Mental disorder—Methotrexate—lymphatic system cancer	0.00068	0.00168	CcSEcCtD
Brimonidine—Erythema—Methotrexate—lymphatic system cancer	0.000676	0.00167	CcSEcCtD
Brimonidine—Nausea—Vincristine—lymphatic system cancer	0.000675	0.00167	CcSEcCtD
Brimonidine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000662	0.00163	CcSEcCtD
Brimonidine—Nausea—Mitoxantrone—lymphatic system cancer	0.000657	0.00162	CcSEcCtD
Brimonidine—Vision blurred—Methotrexate—lymphatic system cancer	0.000637	0.00157	CcSEcCtD
Brimonidine—Cough—Methotrexate—lymphatic system cancer	0.00059	0.00145	CcSEcCtD
Brimonidine—Arthralgia—Methotrexate—lymphatic system cancer	0.000575	0.00142	CcSEcCtD
Brimonidine—Chest pain—Methotrexate—lymphatic system cancer	0.000575	0.00142	CcSEcCtD
Brimonidine—Myalgia—Methotrexate—lymphatic system cancer	0.000575	0.00142	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000571	0.00141	CcSEcCtD
Brimonidine—Discomfort—Methotrexate—lymphatic system cancer	0.000568	0.0014	CcSEcCtD
Brimonidine—Infection—Methotrexate—lymphatic system cancer	0.000548	0.00135	CcSEcCtD
Brimonidine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000541	0.00133	CcSEcCtD
Brimonidine—Skin disorder—Methotrexate—lymphatic system cancer	0.000536	0.00132	CcSEcCtD
Brimonidine—Hypotension—Methotrexate—lymphatic system cancer	0.000515	0.00127	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000502	0.00124	CcSEcCtD
Brimonidine—Insomnia—Methotrexate—lymphatic system cancer	0.000499	0.00123	CcSEcCtD
Brimonidine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000495	0.00122	CcSEcCtD
Brimonidine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000492	0.00121	CcSEcCtD
Brimonidine—Somnolence—Methotrexate—lymphatic system cancer	0.00049	0.00121	CcSEcCtD
Brimonidine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000485	0.0012	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000476	0.00117	CcSEcCtD
Brimonidine—Fatigue—Methotrexate—lymphatic system cancer	0.000475	0.00117	CcSEcCtD
Brimonidine—Pain—Methotrexate—lymphatic system cancer	0.000472	0.00116	CcSEcCtD
Brimonidine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000406	0.001	CcSEcCtD
Brimonidine—Asthenia—Methotrexate—lymphatic system cancer	0.000396	0.000976	CcSEcCtD
Brimonidine—Pruritus—Methotrexate—lymphatic system cancer	0.00039	0.000963	CcSEcCtD
Brimonidine—Dizziness—Methotrexate—lymphatic system cancer	0.000365	0.0009	CcSEcCtD
Brimonidine—Rash—Methotrexate—lymphatic system cancer	0.000348	0.000858	CcSEcCtD
Brimonidine—Dermatitis—Methotrexate—lymphatic system cancer	0.000347	0.000857	CcSEcCtD
Brimonidine—Headache—Methotrexate—lymphatic system cancer	0.000345	0.000852	CcSEcCtD
Brimonidine—Nausea—Methotrexate—lymphatic system cancer	0.000328	0.000808	CcSEcCtD
